<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CUTIVATE- fluticasone propionate lotion </strong><br> PharmaDerm, A division of Nycomed US Inc.<br></p></div>
<h1>CUTIVATE<span class="Sup">®</span><br>(fluticasone propionate) <br>Lotion, 0.05%</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s1"></a><a name="section-1"></a><p></p>
<p class="First">Rx Only</p>
<p><span class="Bold">FOR TOPICAL USE ONLY.</span><br><span class="Bold">NOT FOR OPHTHALMIC, ORAL, OR INTRAVAGINAL USE.</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s4"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">CUTIVATE<span class="Sup">®</span> (fluticasone propionate) Lotion, 0.05% contains fluticasone propionate [S-(fluoromethyl)6α,9-difluoro-11β,17-dihydroxy-16α-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate, 17-propionate], a synthetic fluorinated corticosteroid, for topical dermatologic use. The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents.</p>
<p>Chemically, fluticasone propionate is C<span class="Sub">25</span>H<span class="Sub">31</span>F<span class="Sub">3</span>O<span class="Sub">5</span>S. It has the following structural formula:</p>
<div class="Figure">
<a name="f1"></a><img alt="Structural Formula" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9953df12-a2b4-4d22-b204-746fc29f7a5f&amp;name=cut01-0010-01.jpg">
</div>
<p>Fluticasone propionate is a white to off-white powder with a molecular weight of 500.6. It is practically insoluble in water, freely soluble in dimethyl sulfoxide and dimethylformamide, and slightly soluble in methanol and 95% ethanol.</p>
<p>Each gram of CUTIVATE<span class="Sup">®</span> Lotion contains 0.5mg fluticasone propionate in a base of cetostearyl alcohol, isopropyl myristate, propylene glycol, cetomacrogol 1000, dimethicone 360, citric acid, sodium citrate, and purified water, with imidurea, methylparaben, and propylparaben as preservatives.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s5"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Like other topical corticosteroids, fluticasone propionate has anti-inflammatory, antipruritic, and vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of phospholipase A<span class="Sub">2</span> inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid.</p>
<p>Arachidonic acid is released from membrane phospholipids by phospholipase A<span class="Sub">2</span>.</p>
<p>Although fluticasone propionate has a weak affinity for the progesterone receptor and virtually no affinity for the mineralocorticoid, estrogen or androgen receptors, the clinical relevance as related to safety is unknown. Fluticasone propionate is lipophilic and has strong affinity for the glucocorticoid receptor. The therapeutic potency of glucocorticoids is related to the half-life of the glucocorticoid receptor complex. The half-life of the fluticasone propionate-glucocorticoid receptor complex is approximately 10 hours.</p>
<div class="Section" data-sectionCode="43682-4">
<a name="s6"></a><a name="section-3.1"></a><p></p>
<h2>Pharmacokinetics</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="e6"></a><a name="section-3.1.1"></a><p></p>
<p class="First"><span class="Bold"> Absorption:</span> The extent of percutaneous absorption of topical corticosteroids is determined by many factors, including the vehicle and the integrity of the epidermal barrier. Occlusive dressing enhances penetration. Topical corticosteroids can be absorbed from normal intact skin. <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span> and/or other disease processes in the skin increase percutaneous absorption.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-3.1.2"></a><p></p>
<p class="First"><span class="Bold">Distribution:</span> Following intravenous administration of 1 mg of fluticasone propionate in healthy volunteers, the initial disposition phase for fluticasone propionate was rapid and consistent with its high lipid solubility and tissue binding. The apparent volume of distribution averaged 4.2 L/kg (range, 2.3 to 16.7 L/kg). The percentage of fluticasone propionate bound to human plasma proteins averaged 91%. Fluticasone propionate is weakly and reversibly bound to erythrocytes. Fluticasone propionate is not significantly bound to human transcortin.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-3.1.3"></a><p></p>
<p class="First"><span class="Bold">Metabolism:</span> No metabolites of fluticasone propionate were detected in an in vitro study of radiolabeled fluticasone propionate incubated in a human skin homogenate. The total blood clearance of systemically absorbed fluticasone propionate averages 1093 mL/min (range, 618 to 1702 mL/min) after a 1-mg intravenous dose, with renal clearance accounting for less than 0.02% of the total.</p>
<p>Orally absorbed fluticasone propionate has demonstrated extensive first-pass metabolism with no unchanged drug detected in the plasma up to 6 hours after dosing. Fluticasone propionate is metabolized in the liver by cytochrome P450 3A4-mediated hydrolysis of the 5-fluoromethyl carbothiolate grouping. This transformation occurs in 1 metabolic step to produce the inactive 17β-carboxylic acid metabolite, the only known metabolite detected in man. This metabolite has approximately 2000 times less affinity than the parent drug for the glucocorticoid receptor of human lung cytosol in vitro and negligible pharmacological activity in animal studies. Other metabolites detected in vitro using cultured human <span class="product-label-link" type="condition" conceptid="4101758" conceptname="Hepatocellular carcinoma">hepatoma</span> cells have not been detected in man.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-3.1.4"></a><p></p>
<p class="First"><span class="Bold">Excretion:</span> Following an intravenous dose of 1 mg in healthy volunteers, fluticasone propionate showed polyexponential kinetics and had an average terminal half-life of 7.2 hours (range, 3.2 to 11.2 hours).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-3.1.5"></a><p></p>
<p class="First"><span class="Bold">Special Population (Pediatric):</span> Plasma fluticasone levels were measured in patients 2 years - 6 years of age in an HPA axis suppression study. A total of 13 (62%) of 21 patients tested had measurable fluticasone at the end of 3 - 4 weeks of treatment. The mean ± SD fluticasone plasma values for patients aged under 3 years was 47.7 ± 31.7 pg/mL and 175.5 ± 243.6 pg/mL. Three patients had fluticasone levels over 300 pg/mL, with one of these having a level of 819.81 pg/mL. No data was obtained for patients &lt; 2 years of age.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s11"></a><a name="section-4"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First">CUTIVATE<span class="Sup">®</span> Lotion applied once daily was superior to vehicle in the treatment of <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> in two studies. The two studies enrolled 438 patients with <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> aged 3 months and older, of which 169 patients were selected as having clinically significant* signs of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, infiltration/papulation and erosion/oozing/crusting at baseline. <a href="#t1">Table 1</a> presents the percentage of patients who completely cleared of <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, infiltration/papulation and erosion/oozing/crusting at Week 4 out of those patients with clinically significant baseline signs.</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1: Complete Clearance Rate CUTIVATE<span class="Sup">®</span> Lotion Vehicle</span></caption>
<col align="left" width="26.033%">
<col align="left" width="34.600%">
<col align="left" width="39.367%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">*Clinically significant was defined as having moderate or severe involvement for at least two of the three signs (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, infiltration/papulation, or erosion/oozing/crusting) in at least 2 body regions. Patients who had moderate to severe disease in a single body region were excluded from the analysis.</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top"></td>
<td class="Botrule Rrule Toprule" align="left" valign="top">
<span class="Bold">   CUTIVATE</span><span class="Sup">®</span> <span class="Bold">Lotion</span>
</td>
<td class="Botrule Rrule Toprule" align="left" valign="top"><span class="Bold">   Vehicle</span></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Study 1</td>
<td class="Rrule" align="left" valign="top">   9/45 (20%)</td>
<td class="Rrule" align="left" valign="top">   0/37 (0%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">Study 2</td>
<td class="Botrule Rrule" align="left" valign="top">   7/44 (16%)</td>
<td class="Botrule Rrule" align="left" valign="top">   1/43 (2%)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s12"></a><a name="section-5"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">CUTIVATE<span class="Sup">®</span> (fluticasone propionate) Lotion is indicated for the relief of the inflammatory and pruritic manifestations of <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span> in patients 1 year of age or older. The safety and efficacy of drug use for longer than 4 weeks in this population have not been established. The safety and efficacy of CUTIVATE<span class="Sup">®</span> Lotion in pediatric patients below 1 year of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s13"></a><a name="section-6"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">CUTIVATE<span class="Sup">®</span> Lotion is contraindicated in those patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the components of the preparation (see <a href="#s14">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="s14"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First">
CUTIVATE<span class="Sup">®</span> Lotion contains the excipient imidurea which releases formaldehyde as a breakdown product. Formaldehyde may cause allergic sensitization or irritation upon contact with the skin. CUTIVATE<span class="Sup">®</span> Lotion should not be used in individuals with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to formaldehyde as it may prevent healing or worsen <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>.  </p>
<div class="Section" data-sectionCode="34072-9">
<a name="s15"></a><a name="section-7.1"></a><p></p>
<p class="First"><span class="Bold">General:</span> Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal from treatment. Manifestations of Cushing's syndrome, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, and glucosuria can also be produced in some patients by systemic absorption of topical corticosteroids while on treatment.</p>
<p>Patients applying a potent topical steroid to a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis suppression. This may be done by using cosyntropin (ACTH<span class="Sub">1·24</span>) stimulation testing.</p>
<p>Forty-two pediatric patients (4 months to &lt; 6 years of age) with moderate to severe <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic eczema</span> who were treated with CUTIVATE<span class="Sup">®</span> Lotion for at least 3-4 weeks were assessed for HPA axis suppression and 40 of these subjects applied at least 90% of applications. None of the 40 evaluable patients suppressed, where the sole criterion for HPA axis suppression is a plasma cortisol level of less than or equal to 18 micrograms per deciliter after cosyntropin stimulation. Although HPA axis suppression was observed in 0 of 40 pediatric patients (upper 95% confidence bound is 7.2%), the occurrence of HPA axis suppression in any patient and especially with longer use cannot be ruled out. In other studies with fluticasone propionate topical formulations, adrenal suppression has been observed.</p>
<p>If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids. Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. For information on systemic supplementation, see prescribing information for those products.</p>
<p>Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body <span class="product-label-link" type="condition" conceptid="4041088" conceptname="Mass">mass</span> ratios (see <a href="#s22">PRECAUTIONS: Pediatric Use</a>).</p>
<p>The following local adverse reactions have been reported with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in an approximately decreasing order of occurrence: irritation, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span>, <span class="product-label-link" type="condition" conceptid="4299558" conceptname="Acneiform eruption">acneiform eruptions</span>, hypopigmentation, <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">perioral dermatitis</span>, <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">allergic contact dermatitis</span>, <span class="product-label-link" type="condition" conceptid="442777" conceptname="Generalized infection during labor">secondary infection</span>, <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">skin atrophy</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">hypertrichosis</span>, and <span class="product-label-link" type="condition" conceptid="4273714" conceptname="Miliaria">miliaria</span>.</p>
<p>CUTIVATE Lotion, 0.05% may cause local cutaneous adverse reactions (see <a href="#s24">ADVERSE REACTIONS</a>).</p>
<p>If irritation develops, CUTIVATE<span class="Sup">®</span> Lotion should be discontinued and appropriate therapy instituted. <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Allergic contact dermatitis</span> with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation as with most topical products not containing corticosteroids. Such an observation should be corroborated with appropriate diagnostic patch testing.</p>
<p>If concomitant <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infections</span> are present or develop, an appropriate antifungal or antibacterial agent should be used. If a favorable response does not occur promptly, use of CUTIVATE<span class="Sup">®</span> Lotion should be discontinued until the <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> has been adequately controlled.</p>
<p>CUTIVATE<span class="Sup">®</span> Lotion should not be used in the presence of preexisting <span class="product-label-link" type="condition" conceptid="134118" conceptname="Atrophic condition of skin">skin atrophy</span> and should not be used where <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is present at the treatment site. CUTIVATE<span class="Sup">®</span> Lotion should not be used in the treatment of <span class="product-label-link" type="condition" conceptid="136773" conceptname="Rosacea">rosacea</span> and <span class="product-label-link" type="condition" conceptid="135032" conceptname="Dermatitis due to substances taken internally">perioral dermatitis</span>.</p>
<p>Patients that apply CUTIVATE<span class="Sup">®</span> Lotion to exposed portions of the body should avoid excessive exposure to either natural or artificial sunlight (including tanning booths, sun lamps, etc.).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s16"></a><a name="section-7.2"></a><p></p>
<p class="First"><span class="Bold">Information for Patients:</span> Patients using CUTIVATE<span class="Sup">®</span> Lotion should receive the following information and instructions:</p>
<ol class="Arabic">
<li>CUTIVATE<span class="Sup">®</span> Lotion is to be used as directed by the physician. It is for external use only. Avoid contact with the eyes.</li>
<li>CUTIVATE<span class="Sup">®</span> Lotion should not be used for any disorder other than that for which it was prescribed.</li>
<li>The treated skin area should not be bandaged or otherwise covered or wrapped so as to be occlusive unless directed by the physician.</li>
<li>Patients should report to their physician any signs of local adverse reactions as well as non-healing or worsening of skin condition.</li>
<li>Parents of pediatric patients should be advised not to use this medication in the treatment of diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> unless directed by the physician. CUTIVATE<span class="Sup">®</span> Lotion should not be applied in the diaper areas as diapers or plastic pants may constitute occlusive dressing (see <a href="#s26">DOSAGE AND ADMINISTRATION</a>).</li>
<li>CUTIVATE<span class="Sup">®</span> Lotion should not be used on the face, underarms, or groin areas unless directed by a physician.</li>
<li>CUTIVATE<span class="Sup">®</span> Lotion therapy should be discontinued if control is achieved before 4 weeks. If no improvement is seen within 2 weeks, contact a physician. The safety of the use of CUTIVATE<span class="Sup">®</span> Lotion for longer than 4 weeks has not been established.</li>
<li>Patients should report to their physician if they are allergic to formaldehyde.</li>
<li>Patients that apply CUTIVATE<span class="Sup">®</span> Lotion to exposed portions of the body should follow physician advice and routine precautions to avoid excessive or unnecessary exposure to either natural or artificial sunlight (such as sunbathing, tanning booths, sun lamps, etc.).</li>
</ol>
</div>
<div class="Section" data-sectionCode="34075-2">
<a name="s17"></a><a name="section-7.3"></a><p></p>
<p class="First"><span class="Bold">Laboratory Tests:</span> The cosyntropin (ACTH<span class="Sub">1·24</span>) stimulation test may be helpful in evaluating patients for HPA axis suppression.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="s18"></a><a name="section-7.4"></a><p></p>
<h2>
                           Carcinogenesis, Mutagenesis, and Impairment of Fertility:</h2>
<p class="First">In an oral (gavage) mouse carcinogenicity study, doses of 0.1, 0.3 and 1 mg/kg/day fluticasone propionate were administered to mice for 18 months. Fluticasone propionate demonstrated no tumorigenic potential at oral doses up to 1 mg/kg/day (less than the MRHD in adults based on body surface area comparisons) in this study.</p>
<p>In a dermal mouse carcinogenicity study, 0.05% fluticasone propionate ointment (40 μl) was topically administered for 1, 3 or 7 days/week for 80 weeks. Fluticasone propionate demonstrated no tumorigenic potential at dermal doses up to 6.7 μg/kg/day (less than the MRHD in adults based on body surface area comparisons) in this study.</p>
<p>In a 52 week dermal photo-carcinogenicity study conducted in hairless albino mice with concurrent exposure to low level ultraviolet radiation (40 weeks of treatment followed by 12 weeks of observation),  topically treated lotion vehicle animals and 0.05% fluticasone propionate lotion animals demonstrated shorter time to benign <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumor</span> formation compared to untreated control animals.  Lotion vehicle treated animals developed benign <span class="product-label-link" type="condition" conceptid="135777" conceptname="Neoplasm of uncertain behavior of skin">skin tumors</span> in a shorter time than 0.05% fluticasone propionate lotion treated animals.  Although applicability of results to clinical use of CUTIVATE<span class="Sup">®</span> Lotion in humans is unknown, and enhanced tumor growth in patients treated with CUTIVATE<span class="Sup">®</span> Lotion has not been reported, patients should exercise general precautions in minimizing UV light exposure by avoiding excessive or unnecessary exposure to either natural or artificial sunlight (including sunbathing, tanning booths, sun lamps, etc.)</p>
<p>Fluticasone propionate revealed no evidence of mutagenic or clastogenic potential based on the results of five in vitro genotoxicity tests (Ames assay, <span class="Italics">E. coli</span> fluctuation test, <span class="Italics">S. cerevisiae</span> gene conversion test, Chinese hamster ovary cell chromosome aberration assay and human lymphocyte chromosome aberration assay) and one in vivo genotoxicity test (mouse micronucleus assay).</p>
<p>No evidence of impairment of fertility or effect on mating performance was observed in a fertility and general reproductive performance study conducted in male and female rats at subcutaneous doses up to 50 μg/kg/day (less than the MRHD in adults based on body surface area comparisons).</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="s19"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s20"></a><a name="section-7.5.1"></a><p></p>
<p class="First"><span class="Bold">Teratogenic Effects:</span> Pregnancy Category C. Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals.</p>
<p>Systemic embryofetal development studies were conducted in mice, rats and rabbits. Subcutaneous doses of 15, 45 and 150 μg/kg/day of fluticasone propionate were administered to pregnant female mice from gestation days 6 – 15. A teratogenic effect characteristic of corticosteroids (<span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>) was noted after administration of 45 and 150 μg/kg/day (less than the MRHD in adults based on body surface area comparisons) in this study. No treatment related effects on embryofetal toxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> were noted at 15 μg/kg/day (less than the MRHD in adults based on body surface area comparisons).</p>
<p>Subcutaneous doses of 10, 30 and 100 μg/kg/day of fluticasone propionate were administered to pregnant female rats in two embryofetal development studies (one study administered fluticasone propionate from gestation days 6 – 15 and the other study from gestation days 7 – 17). In the presence of maternal toxicity, fetal effects noted at 100 μg/kg/day (less than the MRHD in adults based on body surface area comparisons) included decreased fetal weights, <span class="product-label-link" type="condition" conceptid="4077297" conceptname="Congenital omphalocele">omphalocele</span>, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>, and retarded skeletal ossification. No treatment related effects on embryofetal toxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> were noted at 10 μg/kg/day (less than the MRHD in adults based on body surface area comparisons).</p>
<p>Subcutaneous doses of 0.08, 0.57 and 4 μg/kg/day of fluticasone propionate were administered to pregnant female rabbits from gestation days 6 – 18. Fetal effects noted at 4 μg/kg/day (less than the MRHD in adults based on body surface area comparisons) included decreased fetal weights, <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> and retarded skeletal ossification. No treatment related effects on embryofetal toxicity or <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> were noted at 0.57 μg/kg/day (less than the MRHD in adults based on body surface area comparisons).</p>
<p>Oral doses of 3, 30 and 300 μg/kg/day fluticasone propionate were administered to pregnant female rabbits from gestation days 8 – 20. No fetal or teratogenic effects were noted at oral doses up to 300 μg/kg/day (less than the MRHD in adults based on body surface area comparisons) in this study. However, no fluticasone propionate was detected in the plasma in this study, consistent with the established low bioavailability following oral administration (see <a href="#s5">CLINICAL PHARMACOLOGY</a>).</p>
<p>Fluticasone propionate crossed the placenta following administration of a subcutaneous or an oral dose of 100 μg/kg tritiated fluticasone propionate to pregnant rats.</p>
<p>There are no adequate and well-controlled studies in pregnant women. During clinical trials of CUTIVATE<span class="Sup">®</span> Lotion, women of childbearing potential were required to use contraception to avoid pregnancy. Therefore, CUTIVATE<span class="Sup">®</span> Lotion should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s21"></a><a name="section-7.6"></a><p></p>
<p class="First"><span class="Bold">Nursing Mothers:</span> Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Because many drugs are excreted in human milk, caution should be exercised when CUTIVATE<span class="Sup">®</span> Lotion is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s22"></a><a name="section-7.7"></a><p></p>
<p class="First"><span class="Bold">Pediatric Use:</span> CUTIVATE<span class="Sup">®</span> Lotion contains the excipient imidurea which releases formaldehyde as a breakdown product. Formaldehyde may cause allergic sensitization or irritation upon contact with the skin. CUTIVATE<span class="Sup">®</span> Lotion should not be used in individuals with <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to formaldehyde as it may prevent healing or worsen <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>.  </p>
<p>
CUTIVATE<span class="Sup">®</span> Lotion should be discontinued if control is achieved before 4 weeks. If no improvement is seen within 2 weeks, contact a physician. The safety of the use of CUTIVATE<span class="Sup">®</span> Lotion for longer than 4 weeks has not been established.</p>
<p>
The safety and efficacy of CUTIVATE<span class="Sup">®</span> Lotion in pediatric patients below 1 year of age have not been established.  </p>
<p>
Parents of pediatric patients should be advised not to use this medication in the treatment of diaper <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span> unless directed by the physician.  CUTIVATE<span class="Sup">®</span> Lotion should not be applied in the diaper areas as diapers or plastic pants may constitute occlusive dressing.</p>
<p>Forty-two pediatric patients (4 months to &lt; 6 years of age) with moderate to severe <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic eczema</span> who were treated with CUTIVATE<span class="Sup">®</span> Lotion for at least 3-4 weeks were assessed for HPA axis suppression and 40 of these subjects applied at least 90% of applications. None of the 40 evaluable patients suppressed, where the sole criterion for HPA axis suppression is a plasma cortisol level of less than or equal to 18 micrograms per deciliter after cosyntropin stimulation. Although HPA axis suppression was observed in 0 of 40 pediatric patients (upper 95% confidence bound is 7.2%), the occurrence of HPA axis suppression in any patient and especially with longer use cannot be ruled out.</p>
<p>In other studies with fluticasone propionate topical formulations, adrenal suppression has been observed. CUTIVATE<span class="Sup">®</span> (fluticasone propionate) Cream, 0.05% caused HPA axis suppression in 2 of 43 pediatric patients, ages 2 and 5 years old, who were treated for 4 weeks covering at least 35% of the body surface area. Follow-up testing 12 days after treatment discontinuation, available for 1 of the 2 patients, demonstrated a normally responsive HPA axis.</p>
<p>HPA axis suppression, Cushing's syndrome, linear <span class="product-label-link" type="condition" conceptid="4245750" conceptname="Growth retardation">growth retardation</span>, delayed <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, and <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include low plasma cortisol levels to an absence of response to ACTH stimulation. Manifestations of <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">intracranial hypertension</span> include bulging fontanelles, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headaches</span>, and bilateral <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span>.  Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen.  Chronic corticosteroid therapy may interfere with the growth and development of children.  </p>
<p>In addition, local adverse events including cutaneous <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>, <span class="product-label-link" type="condition" conceptid="137054" conceptname="Skin striae">striae</span>, <span class="product-label-link" type="condition" conceptid="4010094" conceptname="Telangiectasis">telangiectasia</span>, and <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span> change have been reported with topical use of corticosteroids in pediatric patients.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s23"></a><a name="section-7.8"></a><p></p>
<p class="First"><span class="Bold">Geriatric Use:</span> A limited number of patients above 65 years of age have been treated with CUTIVATE<span class="Sup">®</span> Lotion in US and non-US clinical trials. Specifically only 8 patients above 65 years of age were treated with CUTIVATE<span class="Sup">®</span> Lotion in controlled clinical trials. The number of patients is too small to permit separate analyses of efficacy and safety.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s24"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="e24"></a><a name="section-8.1"></a><p></p>
<p class="First"><span class="Bold">Clinical Trial Experience:</span> In 2 multicenter vehicle-controlled clinical trials of once-daily application of CUTIVATE<span class="Sup">®</span> Lotion by 196 adult and 242 pediatric patients, the total incidence of adverse reactions considered drug related by investigators was approximately 4%. Events were local cutaneous events, usually mild and self-limiting, and consisted primarily of burning/<span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> (2%). All other drug-related events occurred with an incidence of less than 1%, and inclusively were <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">contact dermatitis</span>, exacerbation of <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">atopic dermatitis</span>, <span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">folliculitis</span> of legs, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">pustules</span> on arm, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, and <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">skin infection</span>.</p>
<p>The incidence of drug-related events on drug compared to vehicle (4% and 5%, respectively) was similar. The incidence of drug-related events between study populations of 242 pediatric patients (age 3 months to &lt; 17 years) and 196 adult patients (17 years or older) (4% and 5%, respectively) was also similar.</p>
<p>In an open-label study of 44 pediatric patients applying CUTIVATE<span class="Sup">®</span> Lotion to at least 35% of body surface area twice daily for 3 or 4 weeks, the overall incidence of drug-related adverse events was 14%. Events were local, cutaneous, and inclusively were <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span> (7%), <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> at application site (5%), and <span class="product-label-link" type="condition" conceptid="4219876" conceptname="Excoriation">excoriation</span> (2%).</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2: Drug Related Adverse Events from Controlled Clinical Trials (n=438)</span></caption>
<col align="left" width="35.967%">
<col align="left" width="40.467%">
<col align="left" width="23.567%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top">Adverse Events</td>
<td class="Rrule Toprule" align="left" valign="bottom">     CUTIVATE® Lotion</td>
<td class="Rrule Toprule" align="center" valign="bottom">Vehicle</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule" align="left" valign="top"></td>
<td class="Botrule Rrule" align="left" valign="top">     N=221</td>
<td class="Botrule Rrule" align="center" valign="top">N=217</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Burning/<span class="product-label-link" type="condition" conceptid="4115411" conceptname="Pain of skin">Stinging skin</span></td>
<td class="Rrule" align="left" valign="top">     4 (2%)</td>
<td class="Rrule" align="left" valign="top">     3 (1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact Dermatitis</span></td>
<td class="Rrule" align="left" valign="top">     0</td>
<td class="Rrule" align="left" valign="top">     1 (&lt;1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Exacerbation of <span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic dermatitis</span></td>
<td class="Rrule" align="left" valign="top">     0</td>
<td class="Rrule" align="left" valign="top">     1 (&lt;1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4029295" conceptname="Folliculitis">Folliculitis</span> of legs</td>
<td class="Rrule" align="left" valign="top">     2 (&lt;1%)</td>
<td class="Rrule" align="left" valign="top">     0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Irritant <span class="product-label-link" type="condition" conceptid="134438" conceptname="Contact dermatitis">Contact Dermatitis</span></td>
<td class="Rrule" align="left" valign="top">     0</td>
<td class="Rrule" align="left" valign="top">     1 (&lt;1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="left" valign="top">     1 (&lt;1%)</td>
<td class="Rrule" align="left" valign="top">     1 (&lt;1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4158333" conceptname="Pustule">Pustules</span> on Arms</td>
<td class="Rrule" align="left" valign="top">     1 (&lt;1%)</td>
<td class="Rrule" align="left" valign="top">     0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="left" valign="top">     1 (&lt;1%)</td>
<td class="Rrule" align="left" valign="top">     2 (&lt;1%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">Skin Infection</span></td>
<td class="Botrule Rrule" align="left" valign="top">     0</td>
<td class="Botrule Rrule" align="left" valign="top">     3 (1%)</td>
</tr>
</tbody>
</table>
<a name="t3"></a><table width="100%">
<caption><span>Table 3: Drug Related Adverse Events From Pediatric Open Label Trial (n=44)</span></caption>
<col align="left" width="37.200%">
<col align="left" width="62.800%">
<tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" align="left" valign="top">Adverse Events</td>
<td class="Botrule Rrule Toprule" align="center" valign="top">CUTIVATE<span class="Sup">®</span> Lotion Twice Daily</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">Dry skin</span> at multiple sites</td>
<td class="Rrule" align="center" valign="top">3 (7%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Stinging</span> at Application Sites</td>
<td class="Rrule" align="center" valign="top">2 (5%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4219876" conceptname="Excoriation">Excoriation</span></td>
<td class="Botrule Rrule" align="center" valign="top">1 (2%)</td>
</tr>
</tbody>
</table>
<p>The table below summarizes all adverse events by body system that occurred in at least 1% of patients in either the drug or vehicle group in controlled clinical trials.</p>
<a name="t4"></a><table width="100%">
<caption><span>Table 4: Adverse Events Occurring in ≥ 1% of Patients from Either Arm from Controlled Clinical Trials (n=438)</span></caption>
<col align="left" width="26.433%">
<col align="left" width="29.667%">
<col align="left" width="43.900%">
<tbody class="Headless">
<tr class="First">
<td class="Lrule Rrule Toprule" align="left" valign="top"><span class="Bold">Body System</span></td>
<td class="Rrule Toprule" align="left" valign="bottom">     <span class="Bold">CUTIVATE</span><span class="Sup">®</span><span class="Bold"> Lotion</span>
</td>
<td class="Rrule Toprule" align="left" valign="bottom">     <span class="Bold">Vehicle Lotion</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top">     <span class="Bold">N = 221</span>
</td>
<td class="Rrule" align="left" valign="top">     <span class="Bold">N = 217</span>
</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Any Adverse Event</td>
<td class="Rrule" align="left" valign="top">     77 (35%)</td>
<td class="Rrule" align="left" valign="top">     82 (38%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Skin</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     Burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Stinging</span></td>
<td class="Rrule" align="left" valign="top">     4 (2%)</td>
<td class="Rrule" align="left" valign="top">     3 (1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="left" valign="top">     3 (1%)</td>
<td class="Rrule" align="left" valign="top">     5 (2%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td class="Rrule" align="left" valign="top">     2 (&lt;1%)</td>
<td class="Rrule" align="left" valign="top">     3 (1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="201093" conceptname="Infection of skin AND/OR subcutaneous tissue">Skin Infection</span></td>
<td class="Rrule" align="left" valign="top">     0</td>
<td class="Rrule" align="left" valign="top">     3 (1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Ear, Nose, Throat</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">Common Cold</span></td>
<td class="Rrule" align="left" valign="top">     9 (4%)</td>
<td class="Rrule" align="left" valign="top">     5 (2%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4044878" conceptname="Infection of ear">Ear Infection</span></td>
<td class="Rrule" align="left" valign="top">     3 (1%)</td>
<td class="Rrule" align="left" valign="top">     3 (1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     Nasal <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinus Infection</span></td>
<td class="Rrule" align="left" valign="top">     2 (&lt;1%)</td>
<td class="Rrule" align="left" valign="top">     4 (2%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td class="Rrule" align="left" valign="top">     1 (&lt;1%)</td>
<td class="Rrule" align="left" valign="top">     3 (1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     Upper Respiratory <br>Tract <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td class="Rrule" align="left" valign="top">     6 (3%)</td>
<td class="Rrule" align="left" valign="top">     7 (3%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Gastrointestinal</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     Normal Tooth <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Eruption</span></td>
<td class="Rrule" align="left" valign="top">     2 (&lt; 1%)</td>
<td class="Rrule" align="left" valign="top">     3 (1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td class="Rrule" align="left" valign="top">     3 (1%)</td>
<td class="Rrule" align="left" valign="top">     0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td class="Rrule" align="left" valign="top">     3 (1%)</td>
<td class="Rrule" align="left" valign="top">     2 (&lt;1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Lower Respiratory</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="left" valign="top">     7 (3%)</td>
<td class="Rrule" align="left" valign="top">     6 (3%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span></td>
<td class="Rrule" align="left" valign="top">     5 (2%)</td>
<td class="Rrule" align="left" valign="top">     0</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">Wheeze</span></td>
<td class="Rrule" align="left" valign="top">     0</td>
<td class="Rrule" align="left" valign="top">     3 (1%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Neurology</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="left" valign="top">     4 (2%)</td>
<td class="Rrule" align="left" valign="top">     5 (2%)</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">Non-Site Specific</td>
<td class="Rrule" align="left" valign="top"></td>
<td class="Rrule" align="left" valign="top"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td class="Rrule" align="left" valign="top">     8 (4%)</td>
<td class="Rrule" align="left" valign="top">     8 (4%)</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule" align="left" valign="top">     <span class="product-label-link" type="condition" conceptid="40478941" conceptname="Seasonal allergy">Seasonal Allergy</span></td>
<td class="Botrule Rrule" align="left" valign="top">     2 (&lt;1%)</td>
<td class="Botrule Rrule" align="left" valign="top">     3 (1%)</td>
</tr>
</tbody>
</table>
<p>During the clinical trials, <span class="product-label-link" type="condition" conceptid="137792" conceptname="Eczema herpeticum">eczema herpeticum</span> occurred in a 33-year-old male patient treated with CUTIVATE<span class="Sup">®</span> Lotion. Additionally, a 4-month-old patient treated with CUTIVATE<span class="Sup">®</span> Lotion in the open-label trial had marked elevations of the hepatic enzymes AST and ALT.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="e25"></a><a name="section-8.2"></a><p></p>
<p class="First"><span class="Bold">Post Marketing Experience:</span>  Systemic  adverse events with CUTIVATE<span class="Sup">®</span> Cream and CUTIVATE<span class="Sup">®</span> Ointment have included: <span class="product-label-link" type="condition" conceptid="4242843" conceptname="Immunosuppression">immunosuppression</span>/<span class="product-label-link" type="condition" conceptid="438350" conceptname="Pneumocystosis">Pneumocystis carinii pneumonia</span>/<span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>/<span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>; <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>/ <span class="product-label-link" type="condition" conceptid="434164" conceptname="Glycosuria">glycosuria</span>; Cushing syndrome; generalized body <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>/<span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>; and acute urticarial reaction (<span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, and <span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">throat swelling</span>).
</p>
<p>
The following localized adverse reactions have been reported during post approval use of CUTIVATE® Lotion:  <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>/<span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>, and a reported lack of efficacy.
</p>
<p>
Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.   
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s25"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">Topically applied CUTIVATE<span class="Sup">®</span> Lotion can be absorbed in sufficient amounts to produce systemic effects (see <a href="#s14">PRECAUTIONS</a>).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s26"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">CUTIVATE<span class="Sup">®</span> Lotion may be used in adult and pediatric patients 1 year of age or older. The safety and efficacy of CUTIVATE<span class="Sup">®</span> Lotion in pediatric patients below 1 year of age have not been established (see <a href="#s22">PRECAUTIONS: Pediatric Use</a>).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s27"></a><a name="section-10.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="133834" conceptname="Atopic dermatitis">Atopic Dermatitis</span>:</span> Apply a thin film of CUTIVATE<span class="Sup">®</span> Lotion to the affected skin areas once daily. Rub in gently.</p>
<p>As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary. The safety and efficacy of drug use for longer than 4 weeks have not been established.</p>
<p>CUTIVATE<span class="Sup">®</span> Lotion should not be used with occlusive dressings or applied in the diaper area unless directed by a physician.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s28"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">CUTIVATE<span class="Sup">®</span> Lotion is supplied in
</p>
<p>60 mL bottle             NDC  0462-0434-60<br>
 120 mL bottle            NDC  0462-0434-04</p>
<p>Store between 15° and 30°C (59° and 86°F). Do not refrigerate.</p>
<p>Keep container tightly sealed.</p>
<p>Revised: 05/2011</p>
<p><span class="Bold">PharmaDerm</span><span class="Sup">®</span><br>A division of Nycomed US Inc.<br>
Melville, NY  11747  USA<br>www.pharmaderm.com</p>
<p>Patent No. 7300669</p>
<p>
I8434
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="d89"></a><a name="section-12"></a><p></p>
<h1>
PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 120 ML LABEL
</h1>
<p class="First">
PharmaDerm<span class="Sup">®</span></p>
<p>
NDC 0462-0434-04
</p>
<p><span class="Bold">
CUTIVATE</span><span class="Sup">®</span></p>
<p>
(fluticasone propionate)
</p>
<p><span class="Bold">
Lotion, 0.05%
</span></p>
<p>
For Topical Use Only –
</p>
<p>
Not for ophthalmic, oral
</p>
<p>
or intravaginal use.
</p>
<p>
Rx only                            120 mL
</p>
<div class="Figure">
<a name="f02"></a><img alt="PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 120 ML LABEL" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=9953df12-a2b4-4d22-b204-746fc29f7a5f&amp;name=cut01-0010-02.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CUTIVATE 		
					</strong><br><span class="contentTableReg">fluticasone propionate lotion</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0462-0434</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">TOPICAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>fluticasone propionate</strong> (fluticasone) </td>
<td class="formItem">fluticasone propionate</td>
<td class="formItem">0.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Propylene Glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Ceteth-20</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Isopropyl Myristate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Dimethicone 350</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Cetostearyl Alcohol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Citric Acid Monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Trisodium Citrate Dihydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Imidurea</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Methylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Propylparaben</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0462-0434-60</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0462-0434-04</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">120 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA021152</td>
<td class="formItem">10/05/2009</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span> PharmaDerm, A division of Nycomed US Inc.
							(043838424)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Nycomed US Inc.</td>
<td class="formItem"></td>
<td class="formItem">043838424</td>
<td class="formItem">ANALYSIS</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Nycomed US Inc.</td>
<td class="formItem"></td>
<td class="formItem">174491316</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 5/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>edc17b37-0b6f-417f-88fd-79f0bbf6c46e</div>
<div>Set id: 9953df12-a2b4-4d22-b204-746fc29f7a5f</div>
<div>Version: 5</div>
<div>Effective Time: 20110531</div>
</div>
</div> <div class="DistributorName"> PharmaDerm, A division of Nycomed US Inc.</div></p>
</body></html>
